Although the role of RDV in the treatment for COVID-19 is controversial, we reported that it could provide protective roles in the AKI model by reducing the levels of BUN, SCr, and urinary albumin and the release of inflammatory factors, in particular the NLRP3 inflammasome, alleviating inflammation and pathological scores in kidney tissue. This evidence concerns the gene NLRP3 and acute kidney injury.